Febrile Neutropenia

Question 1

a clinical presentation of fever (one temperature >= 38.5 or three readings >=38 but <=38.5 per 24h) in a neutropenic patient with an uncontrolled neoplasm involving the bone marrow or more usually in a patient undergoing treatment with cytotoxic agents

Answer 1

Febrile neutropenia

Question 2

Two prognostic groups of febrile neutropenic patients

Answer 2

First group - expected short duration of neutropenia and no evidence of hypotension or abdominal or other localizing symptoms

Second group - expected prolonged neutropenia, evidence of sepsis, and end organ compromise , particularly pneumonia.

Question 3

Primary prophylaxis for febrile neutropenia

Answer 3

shortly after completing chemotherapy to reduce the nadir, administers G-CSF to patients receiving cytotoxic regimens associated with a 20% incidence of febrile neutropenia

Question 4

Secondary prophylaxis for febrile neutropenia

Answer 4

administration of CSFs, in patients who have experienced a neutropenic complication from a prior cycle of chemotherapy, dose reduction or delay may be a reasonably considered alternative

Question 5

Recommended management approach for febrile neutropenia

Answer 5

Question 6

Preventive uses of G-CSF

Answer 6

Question 7

Therapeutic uses of G-CSF

Answer 7

Question 8

What dose and schedule should be used?

Answer 8

Question 9

When should therapy begin and end

Answer 9